Insmed

Yahoo Finance • 3 months ago

Is Insmed Incorporated (INSM) the Best Performing Long Term Stock in 2024?

We recently published a list of the 7 Best Performing Long Term Stocks in 2024. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against the other best performing long term stocks in 2024. Aft... Full story

Yahoo Finance • 3 months ago

Is Insmed Inc. (INSM) the Best Performing Stock in 2024?

We recently compiled a list of the 10 Best Performing Stocks in 2024.In this article, we are going to take a look at where Insmed Inc. (NASDAQ:INSM) stands against the other great-performing stocks. Dow Breaks Record The Dow Jones Indust... Full story

Yahoo Finance • 4 months ago

Decoding Insmed Inc (INSM): A Strategic SWOT Insight

Insmed Inc's ARIKAYCE remains a key strength with robust market acceptance. Dependence on third-party manufacturers and suppliers presents a notable weakness. Opportunities for growth lie in potential approvals and commercialization of bre... Full story

Yahoo Finance • 7 months ago

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., June 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of induceme... Full story

Yahoo Finance • 7 months ago

Insmed Announces Proposed $500 Million Public Offering of Common Stock

BRIDGEWATER, N.J., May 28, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it intends to offer... Full story

Yahoo Finance • 7 months ago

Is Insmed Incorporated (NASDAQ:INSM) a Buy According to Hedge Funds?

We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we will dissect whether Insmed Incorporated (NASDAQ:INSM) is a top healthcare pick of elite hedge funds. Challenges in the Health Sector T... Full story

Yahoo Finance • 7 months ago

Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update

— ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Growth Over the First Quarter of 2023— —Company Reports Positive Topline Safety and Tolerability Dat... Full story

Yahoo Finance • last year

Insmed To Present at the Nasdaq 49th Investor Conference

BRIDGEWATER, N.J., Nov. 29, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will pr... Full story

Yahoo Finance • 2 years ago

12 Best Biotech Stocks To Buy Under $20

In this piece, we will take a look at the 12 best biotechnology stocks to buy under $20. For more stocks, head on over to 5 Best Biotech Stocks To Buy Under $20. The biotechnology industry is one of the hottest sectors right now, particul... Full story

Yahoo Finance • 2 years ago

Insiders of Insmed Incorporated (NASDAQ:INSM) are up 17% on their US$1.7m purchase after Insmed Incorporated (NASDAQ:INSM) rose 5.0% last week

Insmed Incorporated (NASDAQ:INSM) insiders who bought shares over the past year were rewarded handsomely last week. The stock rose 5.0%, resulting in a US$134m rise in the company's market capitalisation. As a result, the stock they origin... Full story

Yahoo Finance • 2 years ago

Insmed to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, February 23, 2023

BRIDGEWATER, N.J., Feb. 9, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its... Full story

Yahoo Finance • 2 years ago

Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference

—Topline Data from Phase 2 PK/PD Study of Brensocatib in Patients with Cystic Fibrosis Show Clear Dose Response at all Evaluated Doses— —Treatment Discontinuation Rate of 15% Reported in Postmarketing ARISE Trial of ARIKAYCE® (amikacin li... Full story

Yahoo Finance • 2 years ago

Insmed To Present at the Nasdaq 47th Investor Conference

BRIDGEWATER, N.J., Nov. 30, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will pre... Full story

Yahoo Finance • 3 years ago

Goldman Sachs Sees These 2 ‘Strong Buy’ Stocks Skyrocketing Over 70%

Just when it looked like time to throw in the towel, the market pulled through and delivered a win. After April turned out to be the worst month since March 2020, May kicked off in a more upbeat fashion, with investors hoping the bottom mi... Full story